Toronto, Ontario – The Newswire – October 21, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that the East Midlands Congenital Heart Centre in Leicester, UK has received the VMS+3.0 unit.

This is the second site in the UK to receive the VMS+3.0 as a tool for aiding in the diagnosis and monitoring of patients with heart disease. Regular monitoring and reassessments are especially critical for the care of patients with congenital heart disease (CHD), as well as for managing case load of new patients. The VMS+ system is a tool for regular monitoring and assessments because it provides a rapid and complete visualization of the function of the whole heart.

Dr. Gregory Skinner, MB BS MRCPCH, is one of Ventripoint’s early adopters of the first model of the VMS system and works as a Paediatric Cardiology consultant, specializing in advanced echocardiography at the East Midlands Congenital Heart Centre. Dr. Skinner runs a regular Advanced Echocardiography Imaging Clinic at Glenfield Hospital which is where the new VMS+ 3.0 unit has been installed.

“Being a long term user of the VMS+ system for many years, I am very excited to receive the newest version of the system. I anticipate that the advancements made with the new system will not only enhance the service we already provide, but will allow us to use advanced cardiac function assessment in new settings, including in the intensive care environment,” stated Dr. Skinner

“Every VMS+3.0 installation results in faster and more complete heart analysis for children and adults using conventional ultrasound exams,” commented Dr. George Adams, CEO of Ventripoint.  “With the backlog which has developed due to the COVID-19 pandemic, it is even more important to optimize workflow through imaging centers,” he continued.

The VMS™ Technology

The VMS™ Technology VMS+ (Ventripoint Medical System Plus) 3.0 marries the high-resolution of cardiac MRI (Magnetic Resonance Imaging) and ease of use of ultrasound with the power of Ventripoint's proprietary KBR (Knowledge-Based Reconstruction) AI technology. KBR enables physicians to construct a precise 3D model of the heart and calculate volumes and ejection fractions for all chambers of the heart with an accuracy equivalent to MRI using standard ultrasound images obtained using any cardiac ultrasound machine such as General Electric, Phillips, Siemens, etc.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams

gadams@venripoint.com

519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.